Wockhardt shares continued their impressive rally on Wednesday, May 6, rising for a fourth consecutive session with gains of 19.54% over the last four trading sessions. According to reports from The Economic Times, the stock advanced as much as 8.32% in intraday trading to hit an intraday high of ₹1,640 on the National Stock Exchange (NSE). As of 10:02 am, Wockhardt shares traded 7% higher at ₹1,644, significantly outperforming the NIFTY Smallcap 100 index which was up 0.8%.
The Mumbai-based drugmaker announced exceptional financial performance for the January-March quarter, with standalone net profit surging by a whopping 317% to ₹167 crore compared with ₹40 crore in the same period last year. As reported by The Economic Times, revenue from operations advanced 45% to ₹516 crore, while operating profit (EBITDA) rose 52% to ₹161 crore. On a consolidated basis, Wockhardt's net profit came in at ₹164 crore compared with a loss of ₹25 crore in the year-ago period.
The company's biotech operations demonstrated robust performance with ₹252 crore in quarterly revenue, recording annual growth of 126%. According to The Economic Times, on a full year basis, biotech operations recorded 27% growth while delivering ₹697 crore. The Mumbai-based drugmaker attributed this growth to its emerging market biotech segment growing at >34% on FY25 with accelerated business opportunities and strategic partnerships in key markets including Thailand, Egypt, Algeria and LATAM.
Wockhardt's regional operations showed strong growth across multiple markets. As reported by The Economic Times, India branded business rose 18% to ₹112 crore in Q4, UK business increased 20% to ₹349 crore, emerging market business advanced 124% to ₹320 crore, and Irish region business stood at ₹52 crore, registering growth of 12%. The company filed for 15 filings and got 13 approvals while launching 23 drugs in global markets during the quarter.
